Every material Form 8-K Transcode Therapeutics, Inc. has filed with the SEC since September 28, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
TransCode Therapeutics said its board has started a formal strategic process to evaluate options to maximize the value of the company and its oncology portfolio, including lead candidate TTX-MC138, and has retained Tungsten Advisors as exclusive strategic financial advisor. The filing states there is no assurance the process will produce any transaction, and the company does not plan updates unless the board approves a specific transaction or disclosure is otherwise required.
Board initiated the formal strategic process; announced October 28, 2026
Options listed include licensing or sale of individual assets, partnerships, portfolio transactions and business combinations
Tungsten Advisors engaged as exclusive strategic financial advisor
No updates planned unless a specific transaction is approved or disclosure is required
On October 1, 2026, TransCode Therapeutics made an $840,975 prepayment on its convertible notes with Yorkville under a waiver. The stock's daily VWAP was below the $1.72 Floor Price on 10 of 14 trading days from September 11 to September 30, 2026, which could have triggered monthly repayment obligations. After the prepayment, about $4.1 million of principal remains outstanding, and the waiver covers potential Amortization Events through October 31, 2026.
Prepayment of $840,975 made October 1, 2026: $759,000 principal, $75,900 prepayment premium and $6,075 accrued interest.
Yorkville waived any Amortization Event deemed to have occurred through September 30, 2026, and through October 31, 2026.
Daily VWAP was below the $1.72 Floor Price on 10 of 14 trading days from September 11 to September 30, 2026.
About $4.1 million of principal remains under the Convertible Notes after the prepayment.
TransCode Therapeutics reported updated Phase 1a clinical data for TTX-MC138 in patients with advanced solid tumors, using a September 1, 2026 data cutoff. Ten of 14 efficacy-evaluable patients achieved stable disease, and no dose-limiting toxicities were reported, but the sample is small and disease control was lower at Cycle 6 (35.7%) than at Cycle 3 (57.1%). The filing contains no financial results, so the update bears on the drug's clinical prospects rather than on current financials.
10 of 14 efficacy-evaluable patients (71.4%) achieved stable disease as best overall response at the September 1, 2026 data cutoff.
Disease control rate was 57.1% at Cycle 3 Day 1 and 35.7% at Cycle 6 Day 1.
No dose-limiting toxicities were reported, including at the highest evaluated dose of 4.8 mg/kg, with 98 doses administered.
Post-hoc analysis found 6 of 15 evaluable patients (40%) with a growth modulation index above 1.3; the company said biomarker findings are hypothesis-generating.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Transcode Therapeutics, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →